MannKind (NASDAQ:MNKD – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
MannKind (NASDAQ:MNKD – Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million for the quarter, compared to analyst estimates of $52.36 million. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MannKind Stock Up 2.1 %
Shares of MannKind stock traded up $0.09 during trading on Monday, hitting $4.48. 282,110 shares of the stock traded hands, compared to its average volume of 2,859,315. MannKind has a twelve month low of $3.17 and a twelve month high of $5.75. The company has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $3.92.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on MNKD
MannKind Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Read More
- Five stocks we like better than MannKind
- What is the Australian Securities Exchange (ASX)
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- What is a Special Dividend?
- 3 Value Stocks You Can Buy Before They Become Big
- Dividend Payout Ratio Calculator
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.